¾Ç¼º ¼¶À¯¼ºÁ¶Á÷±¸Á¾¿¡¼ ras À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ
ras Gene Mutations in Malignant Fibrous Histiocytoma
À¯Áø¿µ, À̾ƿø, °¼®Áø, ±èº´±â,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯Áø¿µ ( Yoo Jin-Young )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
À̾ƿø ( Lee Ah-Won )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
°¼®Áø ( Kang Seok-Jin )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
±èº´±â ( Kim Byung-Kee )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
KMID : 0357920010350030232
Abstract
Background: ras gene mutations have been described in various human malignancies, suggesting that their activation may play a role in oncogenesis. However, there are few reports concerning ras gene alterations in malignant fibrous histiocytomas. We therefore designed a study to determine the prevalence and type of mutations in the first exons of H-ras and K-ras genes in these tumors.
Methods: Twenty-seven malignant fibrous histiocytomas were investigated by direct sequencing analysis with the automated DNA sequencing of polymerase chain reaction-amplified ras sequences.
Results: Twenty-four mutations were found in 18 (67%) of the tumors: GGC to GAC transition mutations at codon 13 of K-ras (coding for aspartic acid instead of glycine) in 18 of the samples and GGC to GTC transversions at codon 12 of H-ras (coding for valine instead of glycine) in six of the lesions.
Conclusions: Our data suggest an involvement of the ras gene mutation in conjunction with other yet unknown events in the tumorigenesis and/or progression of malignant fibrous histiocytomas. The K-ras gene activation predominated in these tumors by a mutation at codon 13. It is noteworthy that H-ras mutations were detected only in association with the lesions containing K-ras mutated genes, the significance of which remains to be determined.
Å°¿öµå
Malignant fibrous histiocytoma;H-ras;K-ras
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸